anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Therapy should be continued for at least 24 to 48 hours after symptoms and fever have subsided.

Concomitant therapy: Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium and by iron-containing preparations. Foods and some dairy products also interfere with absorption. Oral forms of tetracycline should be given at least 1 hour before or 2 hours after meals.

In patients with renal impairment: (see WARNINGS). Tetracyclines should be used cautiously in patients with impaired renal function. Total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses.

In patients with liver impairment: Tetracyclines should be used cautiously in patients with impaired liver function. Total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses. Administration of adequate amounts of fluid with the oral formulations of tetracyclines is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration (see ADVERSE REACTIONS).

Adults: Usual daily dose – Four divided doses of 150 mg each or two divided doses of 300 mg each.

For pediatric patients above eight years of age: Usual daily dose, 7 to 13 mg per kg body weight per day, depending upon the severity of the disease, divided into two to four doses not to exceed adult dosage of 600 mg per day.

Gonorrhea patients sensitive to penicillin may be treated with demeclocycline administered as an initial oral dose of 600 mg followed by 300 mg every 12 hours for four days to a total of 3 grams.
The invention provides nucleic acids encoding a TRBP polypeptide, fragments thereof and homologs thereof. The invention also provides TRBP polypeptides, fragments thereof and homologs thereof. The invention further provides assays for identifying compounds that modulate a TRBP bioactivity. Methods for treating diseases or conditions characterized by an aberrant TRBP activity, e.g., by administering to the subject a TRBP therapeutic, are also disclosed. Diseases or conditions that can be treated according to the methods of the invention include thyroid-related disorders, metabolic disorders, and diabetes. Also disclosed are methods for predicting whether a subject is at risk for developing a disease associated with an aberrant TRBP activity, by determining, e.g., whether the subject has a genetic lesion in a TRBP gene.
<P>PROBLEM TO BE SOLVED: To provide a new medicine which inhibits protein kinase.  <P>SOLUTION: There is provided the compound of formula I or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, (particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases). There are also provided a pharmaceutically acceptable composition comprising the compound and methods of utilizing those compounds and compositions in the treatment of various protein kinase-mediated disorders. There is also provided a composition comprising the compound in an amount detectably inhibiting the GSK3, Aurora2, and Syk mammalian protein kinases activity, and a pharmaceutically acceptable carrier, adjuvant or vehicle.  <P>COPYRIGHT: (C)2010,JPO&INPIT
APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
Participants in the control arm were blinded as to the hypothesis of the study, undergoing a series of questions in about general health behaviours before their consultation, allowing the investigators to determine eligibility for the study. The associated participant information sheets for the control arm did not specifically mention breast cancer screening, maintaining blinding throughout. There was no reminder to the physician to promote mammography to participants. The physician continued with his or her usual counseling on health screening and mammography, if any. A 3-minute health promotion video by the Singapore Heart Foundation on healthy eating habits was administered to each participant, followed by a post-consultation questionnaire. The entire process took approximately 10 minutes.
The invention discloses a Xiaojian pill for eliminating hard masses. The invention mainly assists in treating a brain tumor, an esophagus cancer, a stomach cancer, a rectum cancer, a liver cancer, a lung cancer and a bladder cancer. The muscle stiffness pill is an exclusive treatment medicine. Functions of the pill are inflammation diminishing and pain relieving; the pill has strong effect; poisonous matters and poisonous traces in blood can be removed; origins of tumors and cancers in human blood can be removed thoroughly; viruses are eliminated, and patients are cured. The Xiaojian pill for eliminating hard masses is a medicine for oral use. Drug dosage is determined by oneself according to tumor malignant degree of a tumor and a cancer at different body parts. Main components of the Xiaojian pill for eliminating hard masses are Paris polyphylla, bittersweet, dandelion, safflower, ligusticum wallichii, peach seeds, heydyotis diffusa, barbed skullcap, cordate houttuynia, forsythia, densefruit pittany root-bark, ampelopsis japonica, smilax glabra, sparganium, herba cephalanoploris, clam, concha arcae, Liujima, patrinia herb, artemisia capillaries, bletilla striata and poria cocos. The pill has no side effect.
BACKGROUND: Among patients with chronic obstructive pulmonary disease (COPD), some have features of both asthma and COPD-a condition categorized as asthma-COPD overlap (ACO). Our aim was to determine whether asthma- or COPD-related microRNAs (miRNAs) play a role in the pathogenesis of ACO.
METHODS: A total of 22 healthy subjects and 27 patients with ACO were enrolled. We selected 6 miRNAs that were found to correlate with COPD and asthma. The expression of miRNAs and target genes was analyzed using quantitative reverse-transcriptase polymerase chain reaction. Cell apoptosis and intracellular reactive oxygen species production were evaluated using flow cytometry. In vitro human monocytic THP-1 cells and primary normal human bronchial epithelial (NHBE) cells under stimuli with cigarette smoke extract (CSE) or ovalbumin (OVA) allergen or both were used to verify the clinical findings.
RESULTS: We identified the upregulation of miR-125b-5p in patients with ACO and in THP-1 cells stimulated with CSE plus OVA allergen. We selected 16 genes related to the miR-125b-5p pathway and found that IL6R and TRIAP1 were both downregulated in patients with ACO and in THP-1 cells stimulated with CSE plus OVA. The percentage of late apoptotic cells increased in the THP-1 cell culture model when stimulated with CSE plus OVA, and the effect was reversed by transfection with miR-125b-5p small interfering RNA (siRNA). The percentage of reactive oxygen species-producing cells increased in the NHBE cell culture model when stimulated with CSE plus OVA, and the effect was reversed by transfection with miR-125b-5p siRNA. In NHBE cells, siRNA transfection reversed the upregulation of STAT3 under CSE+OVA stimulation.
CONCLUSIONS: Our study revealed that upregulation of miR-125b-5p in patients with ACO mediated late apoptosis in THP-1 cells and oxidative stress in NHBE cells via targeting IL6R and TRIAP1. STAT3 expression was also regulated by miR-125b-5p.
European urological guidelines consider RIRS and ESWL the treatments of choice for renal stones \< 20 mm. RIRS is a endoscopic surgery which allows to rich the kidney from the ureter. A flexible ureteroscope is used for these kind of procedure. Through this device a laser fiber (Holmium laser) is used to treat the stones. After that, small fragments can be removed with a basket. In some cases, according to intraoperative findings, a ureteral stent can be push in the kidney to help the drainage of the kidney. ESWL is a procedure which allows to treat the stones by shock waves generated by a specific machine which work in direct contact with the skin of the patients (extracorporeal). Shockwaves pass all the tissues and finally reach the stones. Such energy allows to break the stones in small fragments, that wll be spontaneously passed by the patients. Specific parameters of these treatments are discussed in "Arms and Interventions". Many studies demonstrated high success rate of RIRS and this technique is becoming more and more adopt. One study demonstrated better outcomes of RIRS versus ESWL, but only for renal stones located in the inferior calices and smaller then 10 mm. There are not other studies comparing the two procedures and there are not proofs that RIRS ensures better outcomes for other renal stones (neither for size nor for location).
PURPOSE: A vector containing anionic polymer for treating non-viral inflammatory diseases is provided to improved gene treatment efficiency. CONSTITUTION: An anti-inflammatory vector for treating inflammatory disease contains anti-inflammatory glucocorticoid and anionic polymer. The anionic polymer is polyethyleneimine. The molecular weight of polyethyleneimine is 5kDa. The anti-inflammatory glucocorticoid is hydrocortisone, dexamethesone, betamethasone, prednisone, prednisolone, triamcinolone, beclomethasone, or cortisonacetate. An anti-inflammatory vector for treating flammatory diseases contains the vector and gene.
BACKGROUND: Endemic domestic dog-ruminant cycles and human cystic echinococcosis caused by Echinococcus granulosus have been sporadically reported in the United States. However, there is a paucity of molecular data describing the genotypes and haplotypes of this important cestode in domestic ruminant hosts.
METHODS: Ninety-four cysts from the lungs and/or livers of slaughtered beef cattle (76 samples), dairy cows (five samples) and sheep (13 samples) were collected from abattoirs in four states of the USA. Samples were genotyped at two mitochondrial loci, cox1 and nad5. Sequences were used to determine species, genotypes and haplotypes using median joining networks and Bayesian phylogenetic analyses. Cyst fertility was assessed in hematoxylin and eosin-stained sections. Additionally, previously reported autochthonous E. granulosus infections in the USA in various hosts were mapped.
RESULTS: Based on cox1 sequences obtained from 94 cysts, 89 (94.7%) were identified as E. granulosus G1/G3, while five (5.3%) were Taenia hydatigena. Taenia hydatigena were only isolated from sheep. Based on nad5 sequences obtained from 89 hydatid cysts, 96.6% and 3.4% belonged to E. granulosus sensu stricto genotypes G1 and G3 respectively. Two haplotypes were found among E. granulosus cox1 sequences, neither of which was geographically unique. Six haplotypes were found among nad5 sequences in genotype G1, of which five were novel, while one haplotype was found in genotype G3. In the concatenated cox1-nad5 dataset, seven haplotypes were identified, of which six were geographically unique. All cysts from cattle were non-fertile. Four cysts from sheep were fertile.
CONCLUSIONS: All genotyped samples belonged to E. granulosus s.s. This is the first study to our knowledge to confirm the presence of genotypes G1 and G3 in domestic cattle and sheep intermediate hosts in the USA and provide data for future diagnostic and epidemiological studies. Sequences have been deposited in GenBank (cox1 sequences: OR398494-OR398496, nad5 sequences: OR400695-OR400702).
Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psoralen inactivated HIV. The number of doses is 3X. The starting dose for an adult is 1×10 9 -1×10 10  . The starting dose for an adolescent is ½(1×10 9 -1×10 10 ). The starting dose for a pediatric patient is ¼(1×10 9 -1×10 10 ). The second dose will consist of 1/10 th  of starting concentrations. The third dose will consist of 1/100 th  of starting concentrations. This will facilitate a Th-1 response. The days of administration are days 1; 30; and 180. Alternatively the days of administration are days 1; 20-40; and 160-200. The site of administration is one that targets lymphatic tissue. Adjuvant is administered before, simultaneous with or after each dose of the immunogenic compositions. Adjuvants are used to promote a Th-1 immune response and include a leukotriene receptor antagonist such as Montelukast, a mast cell and basophil stabilizer such as Cromolyn, and a prostaglandin synthetase inhibitor such as Indomethacin. Th-1 immune responses to the immunogenic compositions are monitored. The 3X cycle will repeat on until a Th-1 immune response is observed. At that point, the immunogenic composition administered could then decline by a factor of 10 for two more vaccination procedures.
Studies TMC114-C213 and TMC114-C202

Studies TMC114-C213 and TMC114-C202 are randomized, controlled, Phase 2b trials in adult subjects with a high level of PI resistance consisting of 2 parts: an initial partially-blinded, dose-finding part and a second long-term part in which all subjects randomized to PREZISTA/ritonavir received the recommended dose of 600/100 mg twice daily.

HIV-1-infected subjects who were eligible for these trials had plasma HIV-1 RNA > 1000 copies/mL, had prior treatment with PI(s), NNRTI(s) and NRTI(s), had at least one primary PI mutation (D30N, M46I/L, G48V, I50L/V, V82A/F/S/T, I84V, L90M) at screening, and were on a stable PI-containing regimen at screening for at least 8 weeks. Randomization was stratified by the number of PI mutations, screening viral load, and the use of enfuvirtide.

The virologic response rate was evaluated in subjects receiving PREZISTA/ritonavir plus an OBR versus a control group receiving an investigator-selected PI(s) regimen plus an OBR. Prior to randomization, PI(s) and OBR were selected by the investigator based on genotypic resistance testing and prior ARV history. The OBR consisted of at least 2 NRTIs with or without enfuvirtide. Selected PI(s) in the control arm included: lopinavir in 36%, (fos)amprenavir in 34%, saquinavir in 35% and atazanavir in 17%; 98% of control subjects received a ritonavir boosted PI regimen out of which 23% of control subjects used dual-boosted PIs. Approximately 47% of all subjects used enfuvirtide, and 35% of the use was in subjects who were ENF-naïve. Virologic response was defined as a decrease in plasma HIV-1 RNA viral load of at least 1 log10 versus baseline.

In the pooled analysis for TMC114-C213 and TMC114-C202, demographics and baseline characteristics were balanced between the PREZISTA/ritonavir arm and the comparator PI arm (see Table 18). Table 18 compares the demographic and baseline characteristics between subjects in the PREZISTA/ritonavir 600/100 mg twice daily arm and subjects in the comparator PI arm in the pooled analysis of Studies TMC114-C213 and TMC114-C202.

Week 96 outcomes for subjects on the recommended dose PREZISTA/ritonavir 600/100 mg twice daily from the pooled Studies TMC114-C213 and TMC114-C202 are shown in Table 19.

In the pooled Studies TMC114-C213 and TMC114-C202 through 48 weeks of treatment, the proportion of subjects with HIV-1 RNA < 400 copies/mL in the arm receiving PREZISTA/ritonavir 600/100 mg twice daily compared to the comparator PI arm was 55.0% and 14.5%, respectively. In addition, the mean changes in plasma HIV-1 RNA from baseline were –1.69 log10 copies/mL in the arm receiving PREZISTA/ritonavir 600/100 mg twice daily and –0.37 log10 copies/mL for the comparator PI arm. The mean increase from baseline in CD4+ cell counts was higher in the arm receiving PREZISTA/ritonavir 600/100 mg twice daily (103 cells/mm3) than in the comparator PI arm (17 cells/mm3).
Low Hb transfusion group; goal to not transfuse unless the Hb \<9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
Methods of forming crosslinked polymer particles in situ from polymer precursors such as monomers or oligomers, comprising exposing a composition comprising at least one polymer precursor, a solvent or solvent mixture, and an antisolvent or antisolvent mixture to photoradiation under conditions whereby particles are formed are provided. The polymer precursor may be photosensitive, or a separate polymerization initiator may be used. In a preferred embodiment, the polymer precursor is insoluble in the antisolvent or antisolvent mixture and the solvent or solvent mixture is soluble in the antisolvent or antisolvent mixture at the concentrations used. Crosslinked polymer particles and crosslinked polymer particles comprising a polymer and a bioactive material are also provided. The polymer may be erodable, and the polymer particles formed may be used in a variety of applications, including controlled release of bioactive materials such as drugs. Polymer particles formed using the methods of the invention have low residual solvent levels and high additive encapsulation efficiencies. The processes of the invention allow control of particle size and morphology, use low operating temperatures and are useful for efficient bulk production.
OBJECTIVES: While fatigue is an extremely common complaint of patients with systemic lupus erythematosus (SLE), the information on factors influencing SLE fatigue in the long term is still limited. This study aims to investigate the actual level of physical activity in the daily life of SLE outpatients and its association with fatigue.
METHODS: In a cross-sectional survey on 93 SLE outpatients we combined clinical assessment with questionnaires to comprehensively assess SLE fatigue, its impact on function and health-related quality of life (hrQoL), and potential contributing factors, with particular emphasis on physical activity.
RESULTS: Fatigue by visual analogue scores and FACIT fatigue scores correlated closely (r=-0.61, p<0.0001). We analysed fatigue in three patient groups, defined by both VAS and FACIT score, as those with severe fatigue, moderate fatigue, and less fatigue. Severe fatigue was associated with greatly diminished hrQoL. SLE patients regularly doing sports showed significantly lower fatigue values than those not doing sports; dog owners were less fatigued than other patients. Fatigue values were not significantly different between employed and unemployed patients. Severe fatigue was also associated with more pain and with shorter sleep duration and worse quality of sleep.
DISCUSSION: This study finds a clear association of fatigue with physical activity, but also with pain and sleep disturbance, and reiterates the impact of fatigue on the SLE patients' quality of life.
This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by consolidation immunotherapy in locally advanced, unresectable NSCLC. In this study, the enrolled patients were divided into the experimental group and the control group at a ratio of 1:1. The patients in the experimental group received anlotinib combined with curative concurrent chemoradiotherapy first, while the patients in the control group received curative concurrent chemoradiotherapy. Those who are evaluated as CR, PR or SD after the aforementioned treatment will enter consolidation immunotherapy. Patients will receive tislelizumab 200mg iv. drip, Q3W, for up to 12 months.
In Pakistan, the 2018 National Nutrition Survey reported that 40% of children under five years old were stunted. This study assessed the effectiveness of nutritional supplementation in reducing stunting among children under five years old in two rural districts in Sindh, Pakistan. This was a mixed-method quasi-experimental study comprising intervention and control populations, with 3397 and 3277 children under five years old participating in the baseline and end-line surveys, respectively. The study areas were similar in terms of demographic and economic circumstances. In the intervention group, pregnant and lactating women (first six months post-partum) received wheat soy blend, children 6-23 months old received Wawamum (lipid-based supplement), and children 24-59 months old received micronutrient powders, all through lady health workers. This was underpinned by nutrition behaviour change communication for appropriate complementary feeding practices and hygiene promotion targeted at primary caregivers. The control group received no intervention. The impact was assessed using the difference-in-difference analysis with kernel propensity score matching to adjust the differences among the control and intervention populations. The overall DID analysis indicated that the intervention did not significantly reduce the prevalence of stunting (under 5 years) [DID = -5.1, p = 0.079]. The adjusted DID indicated a significant decrease of 13% [DID = -13.0, p = 0.001] in the number of stunted children 24-59 months of age at the endline survey. A significant reduction in underweight among children 24-59 months old was also observed (DID = -9.4%, p = 0.014). In conclusion, this evidence further establishes that nutrient uptake through an intervention for a short duration cannot effectively reduce stunting. It requires continuous nutritional supplementation for mothers during the pregnancy and an initial six months of lactation and then nutritional supplementation for children 6-59 months of age underpinned by effective behaviour change communication targeting mothers and other caregivers for improving complementary feeding practices and hygiene promotion.